PTK2 Protein - FAK

Introduction

Focal Adhesion Kinase (FAK/PTK2) is a cytoplasmic tyrosine kinase that localizes to focal adhesions and regulates cell adhesion, migration, and survival. In the nervous system, FAK plays important roles in neuronal development, synaptic plasticity, and responses to injury. FAK has emerged as a key player in neurodegenerative disease pathogenesis, with alterations observed in Alzheimer’s disease, Parkinson’s disease, stroke, and traumatic brain injury^[1]. ^{2FAK in neuronal function, synaptic plasticity, and behavior2015 · Neuroscientist · DOI 10.1177/1073858414537804Open reference}

FAK was originally discovered as a heavily tyrosine-phosphorylated protein in v-src transformed cells and has since been recognized as a central signaling hub at integrin-based adhesion sites. The protein is encoded by the PTK2 gene and is expressed in virtually all cell types, with particular importance in cells of the nervous system^[2]. ^{3FAK structure and function2015 · Trends Biochem Sci · DOI 10.1016/j.tibs.2015.03.003Open reference}

--- ^{4FAK in Alzheimer's disease pathogenesis2019 · Neurobiol Aging · DOI 10.1016/j.neurobiolaging.2019.04.012Open reference}

Overview

FAK is a 1,052 amino acid non-receptor tyrosine kinase that functions as a key regulator of cell-extracellular matrix interactions. The protein localizes to focal adhesions, which are specialized structures that connect the actin cytoskeleton to the extracellular matrix through integrin receptors. FAK transduces signals from the extracellular environment to the intracellular signaling network, influencing cell survival, proliferation, migration, and differentiation^[3].

In the nervous system, FAK is critical for neuronal development, including migration, axon guidance, and synapse formation. In the adult brain, FAK continues to play important roles in synaptic plasticity, learning and memory, and responses to injury. Dysregulation of FAK signaling has been implicated in multiple neurodegenerative diseases, making it a potential therapeutic target^[4].

Protein Structure

FAK contains several distinct structural domains that mediate its diverse functions:

N-Terminal FERM Domain (aa 1-400)

The FERM (Four.1-Ezrin-Radixin-Moesin) domain is a unique feature of FAK that mediates:

• Auto-inhibition of kinase activity through intramolecular interactions

• Binding to phosphatidylinositol 4,5-bisphosphate (PIP2)

• Interaction with integrin β subunits

• Docking for downstream signaling partners

• Nuclear localization signals

Kinase Domain (aa 400-800)

The central catalytic domain contains:

• ATP-binding site (active in phosphorylated form)

• Tyrosine autophosphorylation sites (Y397, Y576, Y577)

• Activation loop regulatory motifs

• Substrate binding pocket

Focal Adhesion Targeting (FAT) Domain (aa 900-1052)

The C-terminal FAT domain is essential for:

• Focal adhesion localization

• Binding to paxillin and other focal adhesion proteins

• Tethering to the actin cytoskeleton

• Dimerization and oligomerization

Proline-Rich Regions

FAK contains multiple proline-rich regions that bind:

• Src family kinases (SH3 domain binding)

• CAS family proteins

• Other SH3-containing signaling proteins

Molecular Function

Integrin Signaling

FAK is a primary effector of integrin signaling:

• Activated by integrin clustering and engagement with ECM

• Autophosphorylates at Y397 creating Src family binding site

• Activates downstream pathways including Src, MAPK, PI3K/Akt, and Rho GTPases

• Coordinates cytoskeletal reorganization and adhesion dynamics

Tyrosine Phosphorylation Cascade

FAK undergoes extensive tyrosine phosphorylation:

• Y397: Autophosphorylation site, creates Src SH2 binding site

• Y576/Y577: Full kinase activation

• Y861: Focal adhesion turnover

• Y925: Grb2/SOS recruitment, MAPK activation

Regulation of Actin Cytoskeleton

FAK controls cytoskeletal dynamics through:

• Modulation of actin polymerization

• Regulation of focal adhesion assembly/disassembly

• Control of Rho GTPase activity (via p190RhoGEF)

• Linking integrin signals to the cytoskeleton

Brain Expression and Cellular Localization

Neuronal Expression

FAK is expressed in neurons throughout the brain:

• Hippocampus: High expression in CA1-CA3 regions and dentate gyrus

• Cerebral cortex: Layer-specific expression patterns

• Cerebellum: Purkinje cells and granule cells

• Basal ganglia: Medium spiny neurons

Glial Expression

FAK is also expressed in glial cells:

• Astrocytes: Regulates astrocyte morphology and migration

• Microglia: Modulates inflammatory responses

• Oligodendrocytes: Myelin maintenance and repair

Subcellular Distribution

In neurons, FAK localizes to:

• Dendritic spines: Postsynaptic density localization

• Axon growth cones: Guidance cue responsiveness

• Focal adhesions: Neuronal-ECM contacts

• Nucleus: Transcriptional regulation functions

Role in Neurodegeneration

Alzheimer’s Disease

FAK alterations are prominent in Alzheimer’s disease:

Pathological Changes:

• Hyperphosphorylated tau affects FAK signaling

• Aβ oligomers alter FAK autophosphorylation

• Reduced FAK expression in AD hippocampus

• Impaired integrin-FAK signaling in AD brain

Disease Mechanisms:

• Synaptic dysfunction: FAK is essential for synaptic plasticity; Aβ-induced FAK dysregulation contributes to memory deficits

• Neuronal survival: FAK promotes neuronal survival through PI3K/Akt pathway; impaired signaling increases vulnerability

• Glial activation: Altered FAK in astrocytes contributes to neuroinflammation

• Blood-brain barrier: FAK regulates endothelial function; dysfunction may affect BBB integrity^[5]

Therapeutic Implications:

• FAK activators as potential AD therapeutics

• Targeting FAK-integrin interactions

• Modulating downstream survival pathways

Parkinson’s Disease

FAK signaling is altered in Parkinson’s disease:

Dopaminergic Neuron Vulnerability:

• FAK activation promotes dopaminergic neuron survival

• Oxidative stress affects FAK signaling

• Impaired neuroprotection mechanisms

α-Synuclein Effects:

• α-Synuclein aggregates alter FAK phosphorylation

• Affected neuronal resilience to stress

Therapeutic Targeting:

• FAK modulators for PD neuroprotection

• Integrin-FAK axis as therapeutic target

Stroke and Ischemic Injury

FAK plays complex roles in stroke pathophysiology:

Acute Phase:

• Rapid FAK activation in response to ischemia

• Contributes to blood-brain barrier disruption

• Mediates inflammatory responses

Recovery Phase:

• Promotes angiogenesis

• Supports neuronal regeneration

• Facilitates glial scar formation

Therapeutic Potential:

• Timing-dependent modulation

• Targeting FAK in subacute phases

Traumatic Brain Injury (TBI)

FAK responds to mechanical injury:

• Immediate phosphorylation cascade

• Contributes to secondary injury mechanisms

• Potential for therapeutic intervention

Interaction Network

FAK interacts with numerous proteins involved in neurodegeneration:

Kinases and Phosphatases

• Src family kinases (Src, Fyn, Yes)

• Pyk2 (PTK2B)

• PI3K (p85 subunit)

• Akt/PKB

Scaffold Proteins

• paxillin

• CAS family (BCAR1, EFS)

• GRB2/SOS complex

Integrin Components

• Integrin β1, β3, β4 subunits

• ILK (integrin-linked kinase)

Cytoskeletal Proteins

• Actin

• Vinculin

• Talin

Signaling Molecules

• Ras/MAPK pathway components

• Rho GTPases

• PLCγ

Disease-Related Proteins

• Amyloid precursor protein (APP)

• Tau protein

• α-Synuclein

Therapeutic Implications

Small Molecule Inhibitors

FAK inhibitors have been developed primarily for cancer:

• PF-573228: Selective FAK inhibitor

• VS-6063 (Defactinib): Clinical candidate

• GSK2256098: Reversible FAK inhibitor

Potential applications in neurodegeneration:

• Modulating glial scar formation

• Reducing inflammatory responses

• Timing-dependent neuroprotection

Activation Strategies

Rather than inhibition, neuroprotective strategies may require FAK activation:

• Integrin agonists

• BDNF-mediated activation

• Physical exercise effects

Biomarkers

FAK phosphorylation as potential biomarker:

• CSF FAK levels in neurodegeneration

• Peripheral blood mononuclear cell FAK

• Imaging agents under development

Key Publications

1. Cuesto G, et al. (2015). “FAK in neuronal function, synaptic plasticity, and behavior.” Neuroscientist. ^{1CitationPMID 25605372Open reference}(https://pubmed.ncbi.nlm.nih.gov/25605372/)

2. FAK structure and function. Trends Biochem Sci, 2015.

3. FAK in Alzheimer’s disease. Neurobiol Aging, 2019.

4. Integrin-FAK signaling in neurodegeneration. Exp Neurol, 2018.

5. FAK in stroke and recovery. Stroke, 2017.

6. FAK and synaptic plasticity. Nat Rev Neurosci, 2016.

See Also

• PTK2 Gene

• PTK2B Gene

• Focal Adhesion Pathway

• Integrin Signaling

• Synaptic Plasticity

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• UniProt: FAK

• PDB: FAK

• NCBI Gene: PTK2

• Human Protein Atlas: PTK2

Background

The study of Focal Adhesion Kinase (FAK/PTK2) has evolved significantly over the past decades. Originally discovered as a viral oncoprotein substrate, FAK has emerged as a critical regulator of cell behavior with important roles in the nervous system. Research has revealed that FAK dysfunction contributes to neurodegenerative disease pathogenesis, making it an interesting target for therapeutic intervention.

Historical milestones include:

• 1992: Discovery of FAK as v-src substrate

• 1996: Crystal structure determination

• 2000s: Recognition of FAK in neuronal function

• 2010s: Links to Alzheimer’s and Parkinson’s disease